Researchers at Thomas Jefferson University have partnered with the Jefferson Clinical Research Institute to begin a trial evaluating the safety of a migraine medication from Biohaven Pharmaceuticals called Vazegepant for use as a potential COVID-19 treatment. The medication — which was just cleared for a phase 3 trial by the FDA for its use on migraines — will be tested in hospitalized COVID-19 patients who require supplemental oxygen.
Vazegepant blocks an enzyme thought to cause inflammation in the brain. Researchers hope that the medication also has the potential to reduce inflammation in the lungs, a severe symptom that often results from COVID-19.
In the study, researchers hope to recruit 120 patients who are COVID-19-positive but not yet on a respirator. The trial will be placebo-controlled, meaning some participants will receive treatment with intranasal Vazegepant for two weeks, while others will receive no medication. The primary goal of this trial is study the safety and efficacy of Vazegepant.